GSK’s $10.6bn Nuvalent bet pays off with second lung cancer drug approval
GSK’s Nelkarmi will now be in direct competition with Roche’s established ALK inhibitor Alecensa.
GSK’s Nelkarmi will now be in direct competition with Roche’s established ALK inhibitor Alecensa.
Saudi Arabia’s pharmaceutical industry is entering a new phase. While local manufacturing remains central to strengthening pharmaceutical security, the ambition is expanding beyond conventional localisation towards an integrated ecosystem built...
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
Anthropic plots IPO amid ongoing foray into drug development
Drug delivery’s next bottleneck isn’t innovation, it’s industrial capacity
Australia starts investigation into OpenAI Medicare breach
How DFE Pharma supports confident continuous manufacturing decisions